Single-institution experience with selective internal radiation therapy for the treatment of primary and secondary hepatic tumors

CURRENT STATUS: POSTED

Kabalan Yammine
Clemenceau Medical Center

Francois G. Kamar
Clemenceau Medical Center

Jason Nasser
Clemenceau Medical Center

Claude Tayar
Clemenceau Medical Center

Marwan Ghosn
Clemenceau Medical Center

Feras Chehade
Clemenceau Medical Center

Jihad Daher
Clemenceau Medical Center

Gregory Nicolas  gregory.nicolas@lau.edu
Clemenceau Medical Center
Corresponding Author
ORCID: 0000-0002-1446-5816

DOI:
10.21203/rs.2.15720/v1

SUBJECT AREAS
Cancer Biology Oncology

KEYWORDS
radioembolization, hepatocellular carcinoma, metastatic liver disease, microspheres
Abstract

Background Numerous studies have demonstrated that radioembolization of the liver with yttrium-90 microspheres provides a survival advantage for patients with unresectable primary or secondary tumors of the liver. The goal of this study was to provide results of the real-world experience of a single center in Lebanon with the use of radioembolization to treat liver-only or liver-dominant tumors.

Methods Patients were included in this retrospective review if they were evaluated for radioembolization between January 2015 and June 2017 and had a lung shunt fraction of 20% or less. Tumor responses were determined using the Response Evaluation Criteria In Solid Tumors.

Results Of the 23 patients treated with radioembolization, 8 had hepatocellular carcinoma, 4 had cholangiocellular carcinoma, and 11 had liver-only or liver-dominant metastases from other primary cancers. All were Middle Eastern, with a median age of 64 years (range 36-87 years), and 14 were men. A majority (n=19) had an initial tumor volume of 49% or less. Most (n=17) had multifocal lesions, and 8 had a history of branched or main portal vein thrombosis. Eighteen patients required arterial coil occlusion. Two patients had their cystic artery occluded, and one of these patients developed cholecystitis, which was successfully treated with antibiotics and supportive care. Only one other patient developed a postradioembolization complication, which was a peptic ulcer and was not thought to be due to arterial reflux of microspheres because both the gastroduodenal and right gastric arteries were occluded. Median time to progression was 7 months (range 3-36 months), and median overall survival from radioembolization was 12 months (range 3-40 months). Tumor responses include complete response for 5 patients and partial response for 13 patients. One patient had stable disease and 4 had progressive disease.

Conclusion While avoiding prophylactic coiling, we had a positive experience with coiling
of the gastroduodenal artery and middle hepatic artery for consolidation of radiotherapy.
Performing radioembolization in a nonreferral, private center in Lebanon resulted in good patient outcomes with a low rate of complications.

Background

Even though a paucity of cancer research in the Middle East exists, the incidence of cancer in the region, especially in Lebanon, continues to rise [1, 2]. Primary liver malignancies are common, being the fifth and ninth most frequently diagnosed malignancy in adult men and women, respectively [3]. Secondary or metastatic liver malignancies are even more common and prove to be a significant cause of morbidity and mortality [3-5].

Transarterial radioembolization (TARE) involves the image-guided percutaneous injection of yttrium-90 (Y-90) microspheres directly into the arteries that feed liver tumors. This application of brachytherapy is particularly valuable in the treatment of primary and secondary liver tumors, considering the radiosensitivity of the liver and its limiting intolerance to external beam radiotherapy [6]. The consensus is that sufficient evidence supports the safety and efficacy of Y-90 microsphere therapy in the treatment of hepatic tumors, both primary and secondary [6, 7].

Radioembolization is particularly efficient as it capitalizes on certain physiological phenomena. Approximately 80% of the blood supply to the normal liver tissue stems from the portal vein, while 90% to 100% of the blood supply to liver tumors stems from the hepatic artery [8, 9]. Furthermore, tumors often have a rich blood supply, as angiogenesis is a critical factor in tumorigenesis [10]. The extensive vascularization of tumors and the relatively narrow diameter of the distal capillary beds allow the selective accumulation of
microspheres in the tumor’s microvasculature. Furthermore, the differential blood supply and advantageously narrow range of Y-90 emission provide effective delivery of high doses of radiation to tumor cells while sparing normal parenchyma [9]. The tumoricidal potential of radioembolization is largely attributable to the focal high-energy beta-radiation emission of Y-90, leading to double-stranded DNA breakage and cell death, with the embolic aspect contributing little to its effect [9, 11].

For the treatment of unresectable hepatocellular carcinoma (HCC), the safety and efficacy of Y-90 microsphere therapy has been well established in large cohort studies, with median overall survival (OS) after radioembolization ranging from 8 to 14.4 months [12, 13]. When combined with systemic chemotherapy, radioembolization in patients with liver-only or liver-dominant metastases affects disease control within the liver and may extend survival; however, hepatic tolerance to radioembolization may influence patient selection for the combination treatment [14, 15].

The aim of this study was to retrospectively examine the survival of 23 patients who underwent radioembolization with Y-90 microspheres in primary and secondary hepatic tumors at a single center in Lebanon. The contribution of pretreatment coil embolization of nontarget arteries to the success and safety profile of the treatment was also evaluated.

Methods

Patients and evaluation

Approval from the Institutional Review Board committee was obtained for this retrospective review, and patient data were de-identified. Patients who were seen in the interventional radiology department for treatment of primary or secondary liver tumors
between January 2015 and June 2017 at Mount Lebanon Hospital, Beirut, Lebanon, were included. Patients were included if they had unresectable primary HCC or metastatic liver disease refractory to chemotherapy. Patients with calculated lung shunt fractions greater than 20% were excluded from radioembolization and therefore not included in this review.

Patients’ baseline liver function was assessed before radioembolization. Eastern Cooperative Oncology Group (ECOG) performance status, Barcelona Clinic Liver Cancer (BCLC) staging, and Child-Pugh class were determined for patients with HCC.

Radioembolization protocol

Imaging by computed tomography (CT) or magnetic resonance and \(^{18}\)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT was obtained by the treating physician to establish a baseline and evaluate the proportion of tumor to liver and the extent of extrahepatic disease. In addition, a pretreatment angiogram was performed to evaluate the anatomy of the vascular tree and identify branches of the hepatic artery for appropriate coiling. The gastroduodenal artery (GDA) was coiled if its origin was within 2 cm of the hepatic bifurcation; the right gastric artery (RGA) was coiled if its origin was distal or close to the position of the infusing microcatheter, and the middle hepatic artery (MHA) was coiled if it was found to be contributing to the tumor supply. Coiling of the cystic artery was performed if it was found close to the infusion site and contributing to the tumor supply.

After anatomical mapping of the hepatic arterial tree and coiling of the appropriate arteries, an attempt was made to detect hepatic-extrahepatic vascular shunts, particularly assessing shunts between the hepatic arterial system to that of the lungs or the
gastrointestinal tract, by administering 148 MBq of $^{99m}$Tc-labeled macroaggregated albumin through a catheter. Subsequently, gamma imaging was obtained, and regions of interest were drawn around the liver and lungs in anterior planar images (Fig. 1). Images were evaluated for extrahepatic uptake, and the pulmonary shunt was calculated. Significant uptake to the gastrointestinal tract guided prophylactic coil embolization of arteries, and patients with significant uptake to the lungs beyond 20% were excluded from radioembolization. Catheter tip placement in the hepatic arterial tree to obtain the values for extrahepatic shunting was identical to tip placement in the subsequent administration of Y-90 microspheres.

Doses were calculated using the body surface area model. Radioembolization was performed using Y-90 resin microspheres (SIR-Spheres®, Sirtex Medical Limited, Sydney, Australia). The Y-90 resin microspheres have a half-life of 64.1 hours, a carrier size of 20 to 60 μm in diameter, a mean and maximum emission range of 2.5 mm and 11 mm, respectively [11, 16].

Tumor response was assessed using Response Evaluation Criteria In Solid Tumors. Survival was measured from time of radioembolization until death or censoring in January 2018.

Results

Of the 23 patients receiving radioembolization, 14 were men and 9 were women, all were Middle Eastern with a median age of 64 years (range, 36-87 years, Table). Patients had an ECOG performance status score of 0 (n=7), 1 (n=14), or 2 (n=2) and bilirubin levels <2 mg/dL (median 0.7; range, 0.08-1.40 mg/dL). Patients were diagnosed with unresectable primary HCC (n=8) or cholangiocarcinoma (n=4) or liver metastases from the following
primary malignancies: colorectal carcinoma (n=3), pancreatic cancer (n=3),
neuroendocrine tumor (n=1), endometrial carcinoma (n=1), ovarian carcinoma (n=1),
esophageal adenocarcinoma (n=1), and ocular melanoma (n=1). Etiologies of HCC
included hepatitis B or C (n=3), alcoholic liver disease (n=3), and nonalcoholic
steatohepatitis (n=2). BCLC stages were A (n=1) or C (n=7), and Child-Pugh class was A
(n=6) or B (n=2).

All patients had lung shunts <20% (median 5.0%; range, 1%-19%). Initial tumor volume
was <24% in 13 patients (57%), 25% to 49% in 6 patients (26%), and 50% to 70% in 4
patients (17%). Five patients (22%) had a single lesion, 1 patient (4%) had 2 lesions, and
17 (74%) had multifocal lesions. Seven patients (30%) received unilobar treatment while
16 (70%) received bilobar treatment in a single session. Bilobar treatment was chosen to
prevent delay in treatment and risk of tumor progression in an untreated lobe, as well as
to avoid the added prohibitive cost of splitting the treatment into 2 sessions over weeks to
months. Eight patients (35%) had a history of branch or main portal vein thrombosis.

Of the 23 patients, 18 required a coil occlusion of one or more arteries: the GDA was
coiled in 14 patients, the RGA in 13 patients, and the MHA in 4 patients. Figures 2 and 3
show successful coiling of the GDA and MHA, respectively. The cystic artery was coiled in
2 patients. The falciform ligament was not coiled in any patient, and no skin ulcers were
observed.

Median time to progression was 7 months (range, 3-36 months), and median OS from
radioembolization was 12 months (range, 3-40 months, Fig. 4A). Survival curves based on
lobar involvement and dose are provided (Fig. 4B, C). Tumor responses included a
complete response for 5 patients and partial response for 13 patients; 1 patient had stable
disease, and 4 had progressive disease. Representative images showing microsphere
distribution and responses are provided (Figs. 5, 6).

Only 2 patients had postoperative complications. One patient had a peptic ulcer. This
patient had undergone coiling of both the RGA and GDA, but the ulcer was not due to
arterial reflux of microspheres. Biopsy by esophagastroduodenoscopy of the gastric
ulcer revealed both the presence of tumor invasion and Y-90 microspheres, which
indicated that the peptic ulcer was due to direct tumor invasion of the stomach. This
invasion was not detected on preoperative CT of the abdomen. The other patient
developed cholecystitis, most likely secondary to coiling of the cystic artery. Coiling was
necessary for consolidation of arterial flow, as tumor feeders from the cystic artery were
present. This patient also had multiple stones in the gallbladder; the presence of stones in
the gallbladder is known to lead to baseline intramural vascular insufficiency [17]. The
cholecystitis was successfully treated with antibiotics and supportive care and did not
require cholecystectomy. Only one other patient underwent cystic artery coiling but did
not experience any complications.

Discussion

This study is the first to report on the real-world experience of treating patients with HCC
or liver metastases using radioembolization with resin microspheres in the Middle East. It
demonstrates the feasibility of performing TARE in the treatment of both primary and
secondary liver tumors in a low-volume, non-referral, private medical center with
subsequent survival benefit and a low rate of complications. Median OS for patients
included in our study is comparable to other recent studies involving mixed tumor types,
ranging from 11.7 to 19.0 months [18, 19].
Radioembolization is an effective treatment for both primary and secondary hepatic tumors; however, it is an intricate procedure that necessitates an intelligent approach in its application. A core step in the procedure is the pretreatment angiogram that maps the arterial tree and identifies hepatico-enteric communicating vessels that are candidates for coil embolization for endovascular skeletonization of the arterial system [7, 20]. Hepatic artery anatomy, and subsequently hepatic tumor blood supply, can often be complicated, and tumors may receive blood from more than one artery, each of which would then require individual radioembolization. However, an alternative exists to this cumbersome procedure. Consolidation of arterial flow, as done by coiling of the MHA for our patients, is a technique that leads to vascular flow redistribution through intrahepatic collateral pathways [21-23]. Ischemic hepatic injury resulting from coiling of variant arterial anatomy is rare, and as such, concern is minimal [22-26]. Coiling allows for better delineation and isolation of tumor blood supply and offers a more targeted and complete treatment that better spares healthy liver parenchyma. This approach also simplifies the procedure by reducing the number of administration sites and the amount of Y-90 microspheres required to achieve the same dose of radiation.

The decision to coil was based on multiple factors. MHA coiling was avoided in patients whose tumors were not perfused by the MHA, as there would be no therapeutic advantage in that case. Coiling of the GDA and RGA was done if the artery was near or distal to the infusion site to avoid nontarget radioembolization and ulceration as a result of reflux of Y-90 microspheres to the stomach, pancreas, or small intestine [27]. Universal coiling of the GDA was not performed, and this did not affect the treatment’s safety profile, which is similar to other reports [25, 28].
Of the 2 patients who experienced serious adverse events, 1 required coiling of the cystic artery. Coil embolization of the cystic artery is a complex decision because it requires balancing the risk of radiation cholecystitis secondary to nontarget radioembolization against the risk of ischemic cholecystitis secondary to coiling of the cystic artery. This measure is therefore only considered if it is impossible to otherwise avoid infusing the cystic artery. It is inaccurate to consider the gallbladder as an end-artery organ, as it receives collaterals from the hepatic gallbladder bed and the GDA, and collaterals often play a more significant role than the cystic artery, making safe coil embolization more likely [29, 30]. Recent studies indicate a lack of benefit to prophylactic coiling of the cystic artery [31, 32]. However, some indicators that should inform the decision to coil include the origin of the cystic artery and the choice of microspheres [29, 32]. Nevertheless, specific criteria have yet to be identified that accurately predict who may be most at risk for either ischemic or radiation cholecystitis [29, 31].

Our study has several limitations, including its retrospective and nonrandomized nature. The patient population was significantly heterogenous, with both primary HCC and various secondary tumors, many of which of carry a worse prognosis, such as pancreatic adenocarcinoma. Furthermore, the small population size allowed for limited analysis of survival and precluded stratification by tumor origin.

Conclusions

This study demonstrates the feasibility of performing TARE in the treatment of both primary and secondary liver tumors in a nonreferral, private center in Lebanon, with good disease response and a low rate of complications. Furthermore, a positive experience with coiling of the GDA and MHA for consolidation of radiotherapy when appropriate, while
avoiding prophylactic coiling, is reported; consistent with the literature [33, 34]. However, cystic artery coil embolization appears to carry a high risk of sequelae, particularly if the patient already has a diseased gallbladder.

References
1. Charafeddine MA, Olson SH, Mukherji D, Temraz SN, Abou-Alfa GK, Shamseddine AI. Proportion of cancer in a Middle Eastern country attributable to established risk factors. BMC Cancer. 2017;17:337.

2. Hamadeh RR, Borgan SM, Sibai AM. Cancer Research in the Arab World: a review of publications from seven countries between 2000-2013. Sultan Qaboos Univ Med J. 2017;17:e147-54.

3. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683-91.

4. Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol. 2006;23:47-63.

5. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:e359-86.

6. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31:1237-48.

7. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23.

8. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969-85.
9. Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, et al. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol. 2016;12:1193-204.

10. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol. 1997;24:203-18.

11. Sangro B, Iñarrairaegui M, Bilbao JL. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56:464-73.

12. Khor AY, Toh Y, Allen JC, Ng DC, Kao YH, Zhu G, et al. Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. Hepatol Int. 2014;8:395-404.

13. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624-36.

14. Gibbs P, Do C, Lipton L, Cade DN, Tapner MJ, Price D, et al. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer. 2015;15:802.

15. Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, et al. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. J Gastrointest Oncol. 2017;8:1079-99.

16. Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210.

17. Matz LR, Lawrence-Brown MM. Ischaemic cholecystitis and infarction of the gallbladder. Aust N Z J Surg. 1982;52:466-71.

18. Paprottka KJ, Schoeppe F, Ingrisch M, Rubenthaler J, Sommer NN, De Toni E, et al. Pretherapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients. Eur J Nucl Med Mol Imaging. 2017;44:1185-93.
19. Schobert I, Chapiro J, Nezami N, Hamm CA, Gebauer B, Lin M, et al. Quantitative imaging biomarkers for yttrium-90 distribution on bremsstrahlung single photon emission computed tomography after resin-based radioembolization. J Nucl Med. 2019; doi:10.2967/jnumed.118.219691.

20. Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38:4824-45.

21. Abdelmaksoud MH, Louie JD, Kothary N, Hwang GL, Kuo WT, Hofmann LV, et al. Consolidation of hepatic arterial inflow by embolization of variant hepatic arteries in preparation for yttrium-90 radioembolization. J Vasc Interv Radiol. 2011;22:1364-71.e1.

22. Bilbao JI, Garrastachu P, Herráiz MJ, Rodriguez M, Inarrairaegui M, Rodriguez J, et al. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors. Cardiovasc Intervent Radiol. 2010;33:523-31.

23. Chuang VP, Wallace S. Hepatic arterial redistribution for intraarterial infusion of hepatic neoplasms. Radiology. 1980;135:295-9.

24. Koehler RE, Korobkin M, Lewis F. Arteriographic demonstration of collateral arterial supply to the liver after hepatic artery ligation. Radiology. 1975;117:49-54.

25. Borggreve AS, Landman A, Vissers CMJ, De Jong CD, Lam M, Monninkhof EM, et al. Radioembolization: Is prophylactic embolization of hepaticoenteric arteries necessary? A systematic review. Cardiovasc Intervent Radiol. 2016;39:696-704.

26. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54:868-78.

27. Lam M, Banerjee S, Louie JD, Abdelmaksoud MHK, Iagaru AH, Ennen RE, et al. Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36:1536-47.
28. Ward TJ, Louie JD, Sze DY. Yttrium-90 radioembolization with resin microspheres without routine embolization of the gastroduodenal artery. J Vasc Interv Radiol. 2017;28:246-53.

29. Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek Jr AA, Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571-92.

30. Polyzonis MB, Tsikaras P, Hytiroglou P, Agios A. Further observations on the vascular system of the gallbladder in man. Bull Assoc Anat (Nancy). 1989;73:25-8.

31. Powerski M, Busse A, Seidensticker M, Fischbach F, Seidensticker R, Strach K, et al. Prophylactic embolization of the cystic artery prior to radioembolization of liver malignancies--an evaluation of necessity. Cardiovasc Intervent Radiol. 2015;38:678-84.

32. Theysohn JM, Müller S, Schlaak JF, Ertle J, Schlosser TW, Bockisch A, et al. Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery. Cardiovasc Intervent Radiol. 2013;36:1015-22.

33. Kim DY, Park BJ, Kim YH, Han KH, Cho SB, Cho KR, et al. Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol. 2015;38:495-501.

34. Li MD, Chu KF, DePietro A, Wu V, Wehrenberg-Klee E, Zurkiya O, et al. Same-day yttrium-90 radioembolization: feasibility with resin microspheres. J Vasc Interv Radiol. 2019;30:314-9.

Tables

Table 1. Patient characteristics and baseline values

| Characteristic                  | Value         |
|--------------------------------|---------------|
| Age, y, median (range)         | 64 (36-87)    |
| Male, n (%)                    | 14 (61)       |
| Ethnicity, (n)                 | Middle Eastern (23) |
| Portal vein thrombosis, n     |               |
| Branched                        | 8             |
| Main                            | 5             |
| ECOG performance status, n |  | 7 | 14 | 2 |
|---------------------------|--|---|----|---|
| BCLC stage for HCC patients only, n |  | 1 | 0 | 7 |
| Child-Pugh class for HCC patients only, n |  | 6 | 2 | 0 |
| Tumor, n |  | 8 | 4 | 3 |
| HCC |  | 3 | 3 | 1 |
| CC |  | 1 | 1 | 1 |
| Metastatic colorectal carcinoma |  | 1 | 1 | 1 |
| Metastatic pancreatic cancer |  | 1 | 1 | 1 |
| Metastatic endometrial cancer |  | 1 | 1 | 1 |
| Metastatic esophageal adenocarcinoma |  | 1 | 1 | 1 |
| Metastatic neuroendocrine tumors |  | 1 | 1 | 1 |
| Metastatic ocular melanoma |  | 1 | 1 | 1 |
| Metastatic ovarian cancer |  | 1 | 1 | 1 |
| Bilirubin, median (range) |  | 0.7 mg/dL (0.08-1.40 mg/dL) |  |  |
| Tumor volume, n (%) |  | <24% | 13 (57%) |  |
| 25-49% |  | 6 (26%) |  |
| 50-70% |  | 4 (17%) |  |
| Number of lesions, n (%) |  | 1 | 5 (22%) |  |
| 2 |  | 1 (4%) |  |
| Multifocal lesions |  | 17 (74%) |  |
| Bilobar disease, n (%) |  | 16 (70%) |  |
| Pretreatment arterial coil occlusion, n |  | Gastroduodenal artery | 14 |  |
|  |  | Right gastric artery | 13 |  |
|  |  | Middle hepatic artery | 4 |  |
|  |  | Cystic artery | 2 |  |

BCLC, Barcelona Clinic Liver Cancer; CC, cholangiocarcinoma; ECOG, Eastern Cooperative
Oncology Group; HCC, hepatocellular carcinoma; y, years.

Abbreviations

BCLC, Barcelona Clinic Liver Cancer
CC, cholangiocarcinoma
CT, computed tomography
ECOG, Eastern Cooperative Oncology Group
FDG, $^{18}$F-fluorodeoxyglucose
GDA, gastroduodenal artery
HCC, hepatocellular carcinoma
MHA, middle hepatic artery
OS, overall survival
PET, positron emission tomography
RGA, right gastric artery
TARE, transarterial radioembolization
Y-90, yttrium-90

Declarations

Acknowledgements

Editorial assistance for this manuscript was provided by Eubio Medical Communications, supported by Sirtex Medical, Inc.

Author contributions

All authors conceived, designed, made contributions to, and understand the full scope of the work. KY and NG drafted, revised, approved, and are accountable for all aspects of the work. JN designed and revised the work.

Compliance with ethical standards

This study was approved by Clemenceau Medical Center Institutional Review Board,
affiliated with Johns Hopkins International.

**Competing interests**

The authors declare they have no competing interests.

**Funding**

This study was funded by Clemenceau Medical Center, affiliated with Johns Hopkins International.

**Consent for publication**

This study has obtained Institutional Review Board approval from Clemenceau Medical Center, and the need for informed consent was waived. For this type of study, consent for publication is not required.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author upon request.

**Figures**
99mTc-labeled macroaggregated albumin scintigraphy is the only method available to calculate the fraction of arterially injected particles reaching the lungs. Calculations used are based on the geometric mean obtained with anterior and posterior conjugated views using regions of interest (ROIs) for liver and lung activities. ROIs were drawn around the lung of equal heights along the ventral-dorsal axis.
Preparatory angiogram of patient with rectal cancer and liver metastasis before radioembolization. The aortogram shows the middle hepatic artery with a coiled gastroduodenal artery.
Figure 3

Status post coiling of the middle hepatic artery for redistribution and consolidation of the hepatic arterial flow.

Figure 4

Kaplan-Meier curves for patients after undergoing transarterial radioembolization with resin microspheres for hepatocellular carcinoma or liver metastases. (A) overall survival, (B) survival by lobe involvement, and (C) survival by dose.
Figure 5

18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) staging of pancreatic neoplasm in 38-year-old man shows innumerable hypermetabolic tumor implants scattered in the left and right lobes of the liver as shown in the 3D image (A) and on the transverse (B) and coronal (C) views. Four months after radioembolization with Y-90 microspheres, 18F-FDG PET/CT imaging shows partial therapeutic response of the liver tumors as demonstrated on the 3D image (D) and on the transverse (E) and coronal (F) views.
Following radioembolization, Y-90 positron emission tomography–computed tomography (PET/CT) imaging shows nonhomogeneous distribution of Y-90 microspheres inside the hepatic parenchyma, as revealed on the 3D PET (A) image and the PET/CT fusion transverse (B), sagittal (C), and coronal (D) views.